Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth

NCT03229759
View directory record Official record
Conditions
Preoperative Skin Preparation
Interventions
Octenidine Dihydrocloride in aqueous solution, Vehicle Control, Saline Control
Drug · Other
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available

A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01685242
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available

Sequential Therapy for the Treatment of Severe Bipolar Depression.

NCT02974010
View directory record Official record
Conditions
Bipolar Depression, Suicidal Ideas, Suicidal Ideation, Suicide, Attempted
Interventions
NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion, Saline Solution Intravenous Infusion
Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Fort Lauderdale, Florida • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Not applicable Interventional

Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 2

NCT03333161
View directory record Official record
Conditions
Infant,Premature
Interventions
Cardiorespiratory monitoring
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 15 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available

A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease

NCT03916042
View directory record Official record
Conditions
Dry Eye
Interventions
Reproxalap Ophthalmic Solution (0.25% Novel Formulation) QID to BID, Vehicle Ophthalmic Solution (0.25% Novel Formulation) QID to BID
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 23, 2026, 12:01 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

NCT06292923
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Foralumab, Placebo
Drug · Other
Lead sponsor
Tiziana Life Sciences LTD
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
North Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Not applicable Interventional Results available

Decision Support for Intraoperative Low Blood Pressure

NCT02726620
View directory record Official record
Conditions
Hypotension
Interventions
Attending real-time decision support, In-room real-time decision support, Attending feedback emails, In-room provider feedback emails, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Pager system, Central neuraxial anesthesia, Non-cardiac surgery, Propofol, Sevoflurane, Desflurane, Isoflurane, Ephedrine, Phenylephrine, Norepinephrine, Epinephrine, Dobutamine, Dopamine, Isoproterenol, Milrinone, Atropine, Glycopyrrolate, Vasopressin, Terlipressin, Sodium Chloride 0.9%, Ringer's lactate, Hydroxyethyl starch solutions, Fresh Frozen Plasma, Packed Red Blood Cells, Albumin solutions, Plasma-Lyte, Lidocaine, Bupivacaine, Levobupivacaine, Ropivacaine, Mepivacaine, Tetracaine, Prilocaine, Procaine, Chloroprocaine, Benzocaine, Articaine
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years to 100 Years
Enrollment
22,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224560
View directory record Official record
Conditions
Epilepsy, Lennox Gastaut Syndrome
Interventions
GWP42003-P, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 23, 2026, 12:01 AM EDT
Terminated Not applicable Interventional

Evaluating the Feasibility of a Stepped-care Approach to Treating Adolescents With Binge and Loss of Control Eating

NCT03404713
View directory record Official record
Conditions
Overweight and Obesity, Pediatric Obesity, Eating, Binge
Interventions
Pathways to Health, Be4U
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
13 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available

Multi-arm Optimization of Stroke Thrombolysis

NCT03735979
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Argatroban, Eptifibatide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Fullerton, California • La Jolla, California + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

NCT03930732
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
51
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Not applicable Interventional

A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery

NCT03115398
View directory record Official record
Conditions
Brain Cancer, Head and Neck Cancer, Lung Cancer, Gastrointestinal Cancer, Cervical Cancer
Interventions
Pedometer-based Walking Program
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02246764
View directory record Official record
Conditions
Ocular Hypertension, Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
19 Years to 99 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Control of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic

NCT01829399
View directory record Official record
Conditions
Application Site Discomfort, Medical Device Discomfort
Interventions
Bupivacaine with Epinephrine, Normal Saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2015 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

NCT06481098
View directory record Official record
Conditions
Obesity
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544763
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 23, 2026, 12:01 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Ghrelin Effect on Beta Cell Function in Health and Disease

NCT01729299
View directory record Official record
Conditions
Diabetes
Interventions
Exendin (9-39), acyl ghrelin, saline
Drug
Lead sponsor
David Dalessio
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

NCT02309385
View directory record Official record
Conditions
Non-Infectious Anterior Uveitis
Interventions
8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops
Drug
Lead sponsor
Aciont Inc
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 3 Interventional Results available

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

NCT03523585
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab deruxtecan, Capecitabine, Lapatinib, Trastuzumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
41
States / cities
Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 2 Interventional

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

NCT05759208
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OK-101, Placebo
Drug
Lead sponsor
Okyo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 4 Interventional Results available

Randomized Controlled Trial for Exparel Hip Fracture

NCT03289858
View directory record Official record
Conditions
Hip Fractures
Interventions
Exparel, Sodium Chloride
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
55 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 23, 2026, 12:01 AM EDT
Recruiting Phase 2 Interventional

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

NCT05488340
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
Drug
Lead sponsor
Locus Biosciences
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Fresno, California • Lancaster, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy

NCT01066715
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
XOMA 052, Placebo
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
67
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 23, 2026, 12:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

NCT00990015
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-04308515, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Oct 23, 2026, 12:01 AM EDT